Home>
US Stocks>
Enanta Pharmaceuticals

Enanta Pharmaceuticals share price today

(ENTA)

Enanta Pharmaceuticals share price is $5.75 & ₹492.49 as on 1 Jan 2025, 2.30 'hrs' IST

$5.75

▲

-0.1

(-1.71%)

Market is closed - opens 8 PM, 02 Jan 2025

View live Enanta Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Enanta Pharmaceuticals from India. Also see the sentimental analysis on Indian investors investing in Enanta Pharmaceuticals. Get details on the Indian mutual funds that are investing in Enanta Pharmaceuticals. Get Analyst recommendations and forecasts along with all the Enanta Pharmaceuticals's financials.

Enanta Pharmaceuticals share price movements

Today's Low: $5.40
Today's High: $6.00
$5.75
6.09%
Downside
Day's Volatility :10.0%
Upside
4.17%
52 Weeks Low: $5.30
52 Weeks High: $17.80
$5.75
7.83%
Downside
52 Weeks Volatility :70.22%
Upside
67.7%

Enanta Pharmaceuticals Returns

Period	Enanta Pharmaceuticals Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-48.61%	-10.0%	0.0%
6 Months	-57.06%	-4.7%	0.0%
1 Year	-45.65%	-0.9%	0.0%
3 Years	-92.24%	-2.4%	-21.2%

Enanta Pharmaceuticals Key Statistics

in dollars & INR

Previous Close	$5.85
Open	$6.0
Today's High	$6.0
Today's Low	$5.3999
Market Capitalization	$121.9M
Today's Volume	$2.8M
52 Week High	$17.8
52 Week Low	$5.3
Revenue TTM	$72.0M
EBITDA	$-120.3M
Earnings Per Share (EPS)	$-5.48
Profit Margin	-160.27%
Quarterly Earnings Growth YOY	-0.66%
Return On Equity TTM	-59.64%

How to invest in Enanta Pharmaceuticals from India?

It is very easy for Indian residents to invest directly in Enanta Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Enanta Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Enanta Pharmaceuticals or ENTA on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Enanta Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Enanta Pharmaceuticals shares which would translate to 0.149 fractional shares of Enanta Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Enanta Pharmaceuticals, in just a few clicks!

Returns in Enanta Pharmaceuticals for Indian investors in Rupees

Investment Value

₹1,00,000

Enanta Pharmaceuticals investment value today

Current value as on today

₹57,215

Returns

₹42,785

(-42.79%)

Returns from Enanta Pharmaceuticals Stock

₹45,652 (-45.65%)

Dollar Returns

₹2,867 (+2.87%)

Indian investors sentiment towards Enanta Pharmaceuticals

44%

Period: Oct 3, 2024 to Jan 1, 2025. Change in 30 Days versus previous period

Search volume for Enanta Pharmaceuticals on INDmoney from India has grown in the last 30 days as on Jan 2, 2025. 44% more investors are searching Enanta Pharmaceuticals in the last 30 days versus the previous period.

Global Institutional Holdings in Enanta Pharmaceuticals

Farallon Capital Management, L.L.C.
9.95%
Vanguard Group Inc
9.35%
BlackRock Inc
8.72%
Krensavage Asset Management, LLC
7.07%
Morgan Stanley - Brokerage Accounts
5.20%
Armistice Capital, LLC
4.72%

Analyst Recommendation on Enanta Pharmaceuticals

Buy

64%Buy

28%Hold

7%Sell

Based on 14 Wall street analysts offering stock ratings for Enanta Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 14 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Enanta Pharmaceuticals

What analysts predicted

Upside of 173.91%

Current:

$5.75

Target:

$15.75

Insights on Enanta Pharmaceuticals

Price Movement
In the last 1 month, ENTA stock has moved down by -32.9%
Decreasing Revenue
Revenue is down for the last 2 quarters, 17.97M → 14.60M (in $), with an average decrease of 18.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -22.65M → -28.82M (in $), with an average decrease of 27.2% per quarter
ENTA vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 20.7% return, outperforming this stock by 63.7%
ENTA vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 38.8% return, outperforming this stock by 131.1%
Price to Sales
ForENTA every $1 of sales, investors are willing to pay $1.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

Enanta Pharmaceuticals Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$205.2M	↓ 0.69%
Net Income	$46.4M	↓ 35.54%
Net Profit Margin	22.6%	↓ 12.22%

	FY20	Y/Y Change
Revenue	$122.5M	↓ 40.31%
Net Income	$-36.2M	↓ 177.98%
Net Profit Margin	-29.53%	↓ 52.13%

	FY21	Y/Y Change
Revenue	$97.1M	↓ 20.74%
Net Income	$-79.0M	↑ 118.41%
Net Profit Margin	-81.38%	↓ 51.85%

	FY22	Y/Y Change
Revenue	$86.2M	↓ 11.24%
Net Income	$-121.8M	↑ 54.13%
Net Profit Margin	-141.31%	↓ 59.93%

	FY23	Y/Y Change
Revenue	$79.2M	↓ 8.07%
Net Income	$-133.8M	↑ 9.91%
Net Profit Margin	-168.95%	↓ 27.64%

	FY24	Y/Y Change
Revenue	$67.6M	↓ 14.61%
Net Income	$-116.0M	↓ 13.28%
Net Profit Margin	-171.58%	↓ 2.63%

	Q2 FY23	Q/Q Change
Revenue	$18.9M	↑ 6.16%
Net Income	$-39.1M	↑ 3.74%
Net Profit Margin	-206.78%	↑ 4.84%

	Q3 FY23	Q/Q Change
Revenue	$18.9M	↑ 0.21%
Net Income	$-28.1M	↓ 28.05%
Net Profit Margin	-148.46%	↑ 58.32%

	Q4 FY23	Q/Q Change
Revenue	$18.0M	↓ 4.91%
Net Income	$-33.4M	↑ 18.86%
Net Profit Margin	-185.56%	↓ 37.1%

	Q1 FY24	Q/Q Change
Revenue	$17.1M	↓ 5.27%
Net Income	$-31.2M	↓ 6.74%
Net Profit Margin	-182.7%	↑ 2.86%

	Q2 FY24	Q/Q Change
Revenue	$18.0M	↑ 5.38%
Net Income	$-22.7M	↓ 27.28%
Net Profit Margin	-126.08%	↑ 56.62%

	Q3 FY24	Q/Q Change
Revenue	$14.6M	↓ 18.72%
Net Income	$-28.8M	↑ 27.21%
Net Profit Margin	-197.32%	↓ 71.24%

	FY19	Y/Y Change
Profit	$205.2M	↓ 0.69%

	FY20	Y/Y Change
Profit	$122.5M	↓ 40.31%

	FY21	Y/Y Change
Profit	$97.1M	↓ 20.74%

	FY22	Y/Y Change
Profit	$83.2M	↓ 14.31%

	FY23	Y/Y Change
Profit	$79.2M	↓ 4.79%

	FY24	Y/Y Change
Profit	$67.6M	↓ 14.61%

	Q2 FY23	Q/Q Change
Profit	$18.2M	↑ 5.71%

	Q3 FY23	Q/Q Change
Profit	$18.3M	↑ 0.12%

	Q4 FY23	Q/Q Change
Profit	$17.4M	↓ 4.94%

	Q1 FY24	Q/Q Change
Profit	$16.4M	↓ 5.35%

	Q2 FY24	Q/Q Change
Profit	$18.0M	↑ 9.36%

	Q3 FY24	Q/Q Change
Profit	$14.6M	↓ 18.72%

	FY19	Y/Y Change
Operating Cash Flow	$71.4M	↑ 144.41%
Investing Cash Flow	$-86.7M	↑ 144.8%
Financing Cash Flow	$2.6M	↓ 41.62%

	FY20	Y/Y Change
Operating Cash Flow	$7.1M	↓ 90.08%
Investing Cash Flow	$19.8M	↓ 122.88%
Financing Cash Flow	$9.0M	↑ 248.99%

	FY21	Y/Y Change
Operating Cash Flow	$-70.0M	↓ 1087.53%
Investing Cash Flow	$37.0M	↑ 86.54%
Financing Cash Flow	$3.1M	↓ 65.71%

	FY22	Y/Y Change
Operating Cash Flow	$-84.8M	↑ 21.12%
Investing Cash Flow	$54.9M	↑ 48.41%
Financing Cash Flow	$20.0M	↑ 550.42%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-32.1M	↑ 133.1%
Investing Cash Flow	$-145.7M	↓ 411.66%
Financing Cash Flow	$199.9M	↓ 9960.63%

Enanta Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Enanta Pharmaceuticals is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Enanta Pharmaceuticals Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Enanta Pharmaceuticals Inc	-34.36%	-57.06%	-45.65%	-92.24%	-90.72%
Regeneron Pharmaceuticals, Inc.	-4.97%	-31.12%	-22.37%	13.59%	91.62%
Biontech Se	-1.42%	42.28%	3.53%	-50.85%	155.61%
Alnylam Pharmaceuticals, Inc.	-6.56%	-6.26%	23.43%	35.31%	102.91%
Vertex Pharmaceuticals Incorporated	-11.88%	-15.14%	-1.95%	80.96%	79.75%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Enanta Pharmaceuticals Inc	NA	NA	0.0	-5.49	-0.6	-0.17	NA	7.03
Regeneron Pharmaceuticals, Inc.	17.61	17.61	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.06	0.51	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Enanta Pharmaceuticals Inc	Buy	$121.9M	-90.72%	NA	-160.27%
Regeneron Pharmaceuticals, Inc.	Buy	$78.3B	91.62%	17.61	33.61%
Biontech Se	Buy	$27.3B	155.61%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$30.4B	102.91%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$103.7B	79.75%	32.84	-4.51%

About Enanta Pharmaceuticals

enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.

Organization	Enanta Pharmaceuticals
Employees	145
CEO	Dr. Jay R. Luly Ph.D.
Industry	Health Technology

Management People of Enanta Pharmaceuticals

Name	Title
Dr. Jay R. Luly Ph.D.	President, CEO & Director
Mr. Paul J. Mellett Jr.	Chief Financial & Administrative Officer
Dr. Yat Sun Or Ph.D.	Senior VP of Research & Development and Chief Scientific Officer
Mr. Nathaniel S. Gardiner J.D.	Consultant
Mr. Brendan Luu	Chief Business Officer
Ms. Jennifer Viera	Senior Director of Investor Relations & Corporate Communications
Mr. Matthew P. Kowalsky J.D.	Chief Legal Officer
Ms. Tara Lynn Kieffer Ph.D.	Chief Product Strategy Officer
Dr. Scott T. Rottinghaus M.D.	Senior VP & Chief Medical Officer

Important FAQs about investing in Enanta Pharmaceuticals from India :

What is Enanta Pharmaceuticals share price today?

Enanta Pharmaceuticals share price today stands at $5.75, Open: $6.00 ; Previous Close: $5.85 ; High: $6.00 ; Low: $5.40 ; 52 Week High: $17.80 ; 52 Week Low: $5.30. The stock opens at $6.00, after a previous close of $5.85. The stock reached a daily high of $6.00 and a low of $5.40, with a 52-week high of $17.80 and a 52-week low of $5.30.

Can Indians buy Enanta Pharmaceuticals shares?

Yes, Indians can invest in the Enanta Pharmaceuticals (ENTA) from India.

With INDmoney, you can buy Enanta Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Enanta Pharmaceuticals at zero transaction cost.

How can I buy Enanta Pharmaceuticals shares from India?

It is very easy to buy Enanta Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Enanta Pharmaceuticals be purchased?

Yes, you can buy fractional shares of Enanta Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Enanta Pharmaceuticals stocks?

To start investing in Enanta Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.